Based on multiomics results, we hypothesize that RUNX3 reshapes the immune interaction potential of tumor cells through the following pathways: (1) enhancement of antigen presentation ability by upregulating MHC class II molecules (e.g., HLA-DRA/DRB1 and CD74), thereby improving tumor cell recognition by the immune system and (2) secretion of inflammatory/chemotactic factors (e.g., S100A8/A9 and CHI3L1) to drive MP migration and chemotaxis. Here, CHI3L1 is linked to neoplasm.